Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

British Journal of Haematology

Volumn 151, Issue 4, 2010, Pages 346-353

  Agathocleous, Agathoclis ^a   Rohatiner, Ama ^a   Rule, Simon ^b   Hunter, Hannah ^b   Kerr, Jonathan Paul ^c   Neeson, Susan M ^d   Matthews, Janet ^a   Strauss, Sandra ^a   Montoto, Silvia ^a   Johnson, Peter ^c   Radford, John ^d   Lister, Andrew ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

B cell malignancies; Bortezomib; Rituximab

Indexed keywords

BORTEZOMIB; RITUXIMAB;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CHEST INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; LETHARGY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; OPTIMAL DRUG DOSE; PATIENT DECISION MAKING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PYRAZINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 77958541490     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08340.x     Document Type: Article

References (50)

1. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. & Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research, 59, 2615-2622.
2. Barr, P.M., Fu, P., Lazarus, H.M., Horvath, N., Gerson, S.L., Koc, O.N., Bahlis, N.J., Snell, M.R., Dowlati, A. & Cooper, B.W. (2009) Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. British Journal of Haematology, 147, 89-96.
3. Chen, C.I., Kouroukis, C.T., White, D., Voralia, M., Stadtmauer, E., Stewart, A.K., Wright, J.J., Powers, J., Walsh, W. & Eisenhauer, E. (2007) Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25, 1570-1575.
4. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-López, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology, 17, 1244-1253.
5. De Martino, G.N. & Slaughter, C.A. (1999) The proteasome, a novel protease regulated by multiple mechanisms. The Journal of Biological Chemistry, 274, 22123-22126.
6. Di Bella, N., Taetle, R., Kolibaba, K.S., Boyd, T.E., Raju, R.N., Barrera, D.N., Cochran, E., Dien, P., Hakimian, D., Lyons, R.M., Schlegel, P.J., Vukelja, S.J., Boston, J., Boehm, K.A., Wang, Y. & Asmar, L. (2010) Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood, 115, 475-480.
7. Dimopoulos, M.A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N.A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J. & Anagnostopoulos, N. (2002) Treatment of Waldenstrom's macroglobulinemia with rituximab. Journal of Clinical Oncology, 20, 2327-2333.
8. Ehrlich, P. (1899) On immunity with special reference to cell life. Proceedings of the Royal Society of London, 66, 424-448.
9. Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., De Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. & Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867-4874.
10. Foran, J.M., Rohatiner, A.Z.S., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P.W.M., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessell, E.M., Souleau, B., Benzohra, A. & Lister, T.A. (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-Cell lymphocytic lymphoma. Journal of Clinical Oncology, 18, 317.
11. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hänel, A., Metzner, B., Pott, C., Hartmann, F., Rothmann, F., Rohrberg, R., Böck, H., Wandt, H., Unterhalt, M. & Hiddemann, W. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, 3064-3071.
12. Fowler, N., Kahl, B.S., Rosen, P., Matous, J., Cashen, A., Jacobs, S., Letzer, J., Amin, B., Williams, M., Ross, M., Smith, S., Saleh, A., Shi, H., Parasuraman, S. & Cheson, B.D. (2009) Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the phase 2 VERTICAL study. Blood (ASH Annual Meeting Abstracts), 114, 933.
13. Friedberg, J.W., Vose, J.M., Kelly, J.L., Young, F., Liesveld, J., Armitage, J.O., Proia, N., Cruttenden, K. & Leonard, J.P. (2009) Bendamustine, bortezomib and rituximab in patients (pts) relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter phase II clinical trial. Blood (ASH Annual Meeting Abstracts), 114, 924.
14. Gerecitano, J., Portlock, C., Moskowitz, C., Hamlin, P., Straus, D., Zelenetz, A.D., Zhang, Z., Dumitrescu, O., Sarasohn, D., Lin, D., Pappanicholaou, J., Cortelli, B.M., Neylon, E., Hamelers, R., Wright, J. & O'Connor, O.A. (2009) Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. British Journal of Haematology, 146, 652-655.
15. Gertz, M.A., Rue, M., Blood, E., Kaminer, L.S., Vesole, D.H. & Greipp, P.R. (2004) Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leukaemia and Lymphoma, 45, 2047-2055.
16. Ghielmini, M., Schmitz, S.H., Cogliatti, S., Bertoni, F., Waltzer, U., Fey, M.F., Betticher, D.C., Schefer, H., Pichert, G., Stahel, R., Ketterer, N., Bargetzi, M. & Cerny, T. (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of Clinical Oncology, 23, 705-711.
17. Ghobrial, I.M., Hong, F., Padmanabhan, S., Badros, A., Rourke, M., Leduc, R., Chuma, S., Kunsman, J., Warren, D., Harris, B., Sam, A., Anderson, K.C., Richardson, P.G., Treon, S.P., Weller, E. & Matous, J. (2010) Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia. Journal of Clinical Oncology, 28, 1422-1428.
18. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J.E., Hagemeister, F., Fayad, L., Dang, N.H., Samaniego, F., Wang, M., Broglio, K., Samuels, B., Gilles, F., Sarris, A.H., Hart, S., Trehu, E., Schenkein, D., Cabanillas, F. & Rodriguez, A.M. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 667-675.
19. Hainsworth, J.D., Burris, III, H.A., Morrissey, L.H., Litchy, S., Scullin, Jr, D.C., Bearden, III, J.D., Richards, P. & Greco, F.A. (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood, 95, 3052-3056.
20. Hainsworth, J.J., Litchy, S., Burris, III, H.A., Scullin, Jr, D.C., Corso, S.W., Yardley, D.A., Morrissey, L. & Greco, F.A. (2002) Rituximab as first line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 20, 4261-4267.
21. Herold, M., Haas, A., Srock, S., Neser, S., Haifa Al-Ali, K., Neubauer, A., Dölken, G., Naumann, R., Knauf, W., Freund, M., Rohrberg, R., Höffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Aßmann, M. & Von Grünhagen, U. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology, 25, 1986-1992.
22. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H., Freund, M., Wörmann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trümper, L., Aldaoud, A., Parwaresch, R. & Unterhal, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732.
23. Howard, O.M., Gribben, J.G., Neuberg, D.S., Grossbard, M., Poor, C., Janicek, M.J. & Shipp, M.A. (2002) Rituximab and chop induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. Journal of Clinical Oncology, 20, 1288-1294.
24. Kahl, B.S., Li, H., Smith, M.R., Gascoyne, R.D., Paietta, E., Advani, R. & Horning, S.J. (2009) The VcR-CVAD regimen produces a high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405 - a phase II study of VcR-CVAD with maintenance rituximab for MCL. Blood (ASH Annual Meeting Abstracts), 2009, 1661.
25. Kimby, E., Treon, S.P., Anagoostopoulos, A., Dimopoulos, M., Garcia-Sanz, R., Gertz, M.A., Johnson, S., LeBlond, V., Fermand, J.P., Maloney, D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R., Stone, M. & Bladé, J. (2006) Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clinical Lymphoma & Myeloma, 6, 380-383.
26. Kropff, M., Reis, H., Freund, M., Wörmann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trümper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732.
27. Leleu, X., Eeckhoute, J., Jia, X., Roccaro, A.M., Moreau, A., Farag, M., Sacco, A., Ngo, H.T., Runnels, J., Melhem, M., Burwick, N., Azab, A., Azab, F., Hunter, Z., Hatjiharissi, E., Carrasco, D.R., Treon, S.P., Witzig, T.E., Hideshima, T., Brown, M., Anderson, K.C. & Ghobrial, I.M. (2007) Targeting NF-Kappa B in Waldenstrom macroglobulinemia. Blood, 111, 5068-5077.
28. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., Martin, S., Heidemann, E., Aldaoud, A., Parwaresch, R., Hasford, J., Unterhalt, M. & Hiddemann, W. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Journal of Clinical Oncology, 23, 1984-1992.
29. Leonard, J.P., Furman, R.R., Cheung, Y.K., Feldman, E.J., Cho, H.J., Vose, J.M., Nichols, G., Glynn, P.W., Joyce, M.A., Ketas, J., Ruan, J., Carew, J., Niesvizky, R., LaCasce, A., Chadburn, A., Cesarman, E. & Coleman, M. (2005) Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B Cell (DLBCL) and mantle cell lymphoma (MCL): phase I results. Blood (ASH Annual Meeting Abstracts), 106, 491.
30. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 1417-1423.
31. McLaughlin, P., Grillo-Lopez, J.A., Link, B.R., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.
32. Mitsiades, C.S., Mitsiades, N., Richardson, P.G., Treon, S.P. & Anderson, K.C. (2003) Novel biologically based therapies for Waldenstrom's macroglobulinemia. Seminars in Oncology, 30, 309-312.
33. O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. & Zelenetz, A.D. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676-684.
34. O'Connor, O.A., Hamlin, P., Moskowitz, C., Straus, D., Noy, A., Wright, J., Neylon, E., MacGregor-Cortelli, B., Portlock, C. & Zelenetz, A. (2007) Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 25, 8051.
35. Van Oers, M.H.J., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E., Gascoyne, R.D., Jack, A., Mars van't Veer, A.V., Holte, H., Van Glabbeke, M., Teodorovic, I., Rozewicz, C. & Hagenbeek, A. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108, 3295-3301.
36. Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D., Elliott, P.J., Pien, C.S., Guerciolini, R., Anderson, J.K., Depcik-Smith, N.D., Bhagat, R., Lehman, M.J., Novick, S.C., O'Connor, O.A. & Soignet, S.L. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology, 20, 4420-4427.
37. Ribrag, V., Gisselbrecht, C., Haioun, C., Salles, G., Golfier, J., Marjan, E., Ferme, C., Briere, J., Brice, P. & Mounier, N. (2009) Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer, 115, 4540-4546.
38. Richardson, P.G., Briemberg, H., Jagannath, S., Wen, P.Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D.S., Irwin, D., Schuster, M., Srkalovic, G., Alexanian, R., Rajkumar, S.V., Limentani, S., Alsina, M., Orlowski, R.Z., Najarian, K., Esseltine, D., Anderson, K.C. & Amato, A.A. (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology, 24, 3113-3120.
39. Roccaro, A.M., Leleu, X., Sacco, A., Jia, X., Melhem, M., Moreau, A., Ngo, H.T., Runnels, J., Azab, A., Azab, F., Burwick, N., Farag, M., Treon, S.P., Palladino, M.A., Hideshima, T., Chauhan, D., Anderson, K.C. & Ghobrial, I.M. (2007) Dual targeting of the proteasome regulates survival and homing in Waldenström macroglobulinemia. Blood, 111, 4752-4763.
40. Ruan, J., Martin, P., Furman, R.R., Vose, J.M., LaCasce, A., Cheung, Y.K., O'Loughlin, J., Elstrom, R., Niesvizky, R., Chadburn, A., Ely, S., Cesarman, E.l., Coleman, M. & Leonard, J.P. (2009) CHOP-R + bortezomib as initial therapy for mantle cell lymphoma (MCL). Blood (ASH Annual Meeting Abstracts), 114, 2682.
41. San Miguel, J.F., Richardson, P., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W., Boral, A., Schenkein, D. & Anderson, K. (2008) Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood, 106, 366. Abstract.
42. Sehn, L.H., Macdonald, D.A., Rubin, S.H., Cantin, G., Rubinger, M., Lemieux, B., Basi, S., Imrie, K.R., Gascoyne, R.D., Chen, B., Djurfeldt, M., Shepherd, L., Couban, S. & Crump, M. (2009) Bortezomib added to CVP-R is safe and effective for previously untreated advanced stage follicular lymphoma: a phase II study by the NCIC Clinical Trials Group. Blood (ASH Annual Meeting Abstracts), 2009, 114.
43. Strauss, S.J., Maharaj, L., Hoare, S., Johnson, P.W., Radford, J.A., Vinnecombe, S., Millard, L., Rohatiner, A., Boral, A., Trehu, E., Schenkein, D., Balkwill, F., Joel, S.P. & Lister, T.A. (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. Journal of Clinical Oncology, 24, 2105-2112.
44. Tobinai, K. (2002) Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. International Journal of Hematology, 76, 411-419.
45. Treon, S.P., Agus, T.B., Link, B., Rodrigues, G., Molina, A., Lacy, M.Q., Fisher, D.C., Emmanouilides, C., Richards, A.I., Clark, B., Lucas, M.S., Schlossman, R., Schenkein, D., Lin, B., Kimby, E., Anderson, K.C. & Byrd, J.C. (2001) CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. Journal of Immunotherapy, 24, 272-279.
46. Treon, S.P., Emmanouilides, C., Kimby, E., Kelliher, A., Preffer, F., Branagan, A.R., Anderson, K.C. & Frankel, S.R. (2005) Extended rituximab therapy in Waldenström's macroglobulinemia. Annals of Oncology, 16, 132-138.
47. Treon, S.P., Hunter, Z.R., Matous, J., Joyce, R.M., Mannion, B., Advani, R., Cook, D., Songer, J., Hill, J., Kaden, B.R., Sharon, D., Steiss, R., Leleu, X., Branagan, A.R. & Badros, A. (2007) Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clinical Cancer Research, 13, 3320-3325.
48. Treon, S.P., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Sheehy, P., Nelson, M., Willen, M., Matous, J., Mattern, J., Jakow, J., Diener, J.G., Keogh, G.P., Myers, T.J., Boral, A., Birner, A., Esseltine, D.L. & Ghobrial, I.M. (2009) Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. Journal of Clinical Oncology, 27, 3830-3835.
49. De Vos, S., Goy, A., Dakhil, S.R., Saleh, M.N., McLaughlin, P., Belt, R., Flowers, C.R., Knapp, M., Hart, L., Patel-Donnelly, D., Glenn, M., Gregory, S.A., Holladay, C., Zhang, T. & Boral, A.L. (2009) Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-Cell lymphoma. Journal of Clinical Oncology, 27, 5023-5030.
50. Witzig, T.E., Vukov, A.M., Habermann, T.M., Geyer, S., Kurtin, P.J., Friedenberg, W.R., White, W.L., Chalchal, H.I., Flynn, P.J., Fitch, T.R. & Welker, D.A. (2005) Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. Journal of Clinical Oncology, 23, 1103-1108.